Clinical Aspects of Phage Therapy

Advances in Virus Research

Volumn 83, Issue , 2012, Pages 73-121

  Miedzybrodzki, Ryszard ^a,d   Borysowski, Jan ^b   Weber Dabrowska, Beata ^a   Fortuna, Wojciech ^a   Letkiewicz, Sławomir ^a,c   Szufnarowski, Krzysztof ^a,d   Pawełczyk, Zdzisław ^a   Rogóz, Paweł ^a,e   Kłak, Marlena ^a   Wojtasik, Elzbieta ^b   Górski, Andrzej ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c KATOWICE SCHOOL OF ECONOMICS   (Poland)

^d Regional County Hospital and Research Center   (Poland)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Adverse reactions; Bacterial infection; Bacteriophage; Clinical efficacy; Phage therapy

Indexed keywords

EID: 84862897331     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394438-2.00003-7     Document Type: Chapter

References (50)

1. Adams M.H. Bacteriophages 1959, Interscience Publishers, Inc., New York.
2. Aiello A.E., King N.B., Foxman B. Antimicrobial resistance and the ethics of drug development. Am. J. Publ. Health 2006, 96:1-5.
3. Balogh B., Jones J.B., Iriarte F.B., Momol M.T. Phage therapy for plant disease control. Curr. Pharm. Biotechnol. 2010, 11:48-57.
4. Biswas B., Adhya S., Washart P., Paul B., Trostel A.N., Powell B., Carlton R., Merril C.R. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 2002, 70:204-210.
5. Bruttin A., Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 2005, 49:2874-2878.
6. Capparelli R., Parlato M., Borriello G., Salvatore P., Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 2007, 51:2765-2773.
7. Clokie M.R.J., Kropinski A.M. Bacteriophages: Methods and Protocols 2009, Vol. 1. Humana Press, New York.
8. Freire-Moran L., Aronsson B., Manz C., Gyssens I.C., So A.D., Monnet D.L., Cars O. ECDC-EMA Working Group: Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat. 2011, 14:118-124.
9. Giamarellou H. Multidrug-resistant Gram-negative bacteria: How to treat and for how long. Int. J. Antimicrob. Agents 2010, 36(Suppl. 2):S50-S54.
10. Goerke C., Gressinger M., Endler K., Breitkopf C., Wardecki K., Stern M., Wolz C., Kahl B.C. High phenotypic diversity in infecting but not in colonizing Staphylococcus aureus populations. Environ. Microbiol. 2007, 9:3134-3142.
11. Górski A., Miedzybrodzki R., Borysowski J., Dabrowska K., Wierzbicki P., Ohams M., Korczak-Kowalska G., Olszowska-Zaremba N., Łusiak-Szelachowska M., Kłak M., Jończyk E., Kaniuga E., et al. Phage as modulator of immune responses: Practical implications for phage therapy. In Advances in Virus Research 2012, Elsevier, UK, Vol. Part B, Chapter 2, pp. 41-72. M. Łobocka, W. Szybalski (Eds.).
12. Górski A., Miedzybrodzki R., Borysowski J., Weber-Dabrowska B., Łobocka M., Fortuna W., Letkiewicz S., Zimecki M., Filby G. Bacteriophage therapy for the treatment of infections. Curr. Opin. Invest. Drugs 2009, 10:766-774.
13. Górski A., Wazna E., Weber-Dabrowska B., Dabrowska K., Świtała-Jeleń K., Miedzybrodzki R. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 2006, 46:313-319.
14. Hanlon G.W. Bacteriophages: An appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrob. Agents 2007, 30:118-128.
15. Jabes D. The antibiotic R&D pipeline: An update. Curr. Opin. Microbiol. 2011, 14:564-569.
16. Jasieński J. Próby zastosowania bakteriofagji w chirurgji. Pol Gaz Lek 1927, 4:67-73. [In Polish].
17. Kalinowski W., Czyz J. Sprawozdanie z epidemji czerwonki w roku 1922. Lekarz Wojsk. 1923, 4:286-293. [In Polish].
18. Köck R., Becker K., Cookson B., van Gemert-Pijnen J.E., Harbarth S., Kluytmans J., Mielke M., Peters G., Skov R.L., Struelens M.J., Tacconelli E., Navarro Torné A., et al. Methicillin-resistant Staphylococcus aureus (MRSA): Burden of disease and control challenges in Europe. Euro Surveill. 2010, 15:19688.
19. Kutateladze M., Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010, 28:591-595.
20. Labrie S.J., Samson J.E., Moineau S. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 2010, 8:317-327.
21. Letkiewicz S., Miedzybrodzki R., Fortuna W., Weber-Dabrowska B., Górski A. Eradication of Enterococcus faecalis by phage therapy in chronic prostatitis: Case report. Folia Microbiol. 2009, 54:457-461.
22. Lityński M. Treatment of infection of E. coli using specific bacteriophages. Przegl Lek 1950, 6:13-19.
23. Mahony J., McAuliffe O., Ross R.P., van Sinderen D. Bacteriophages as biocontrol agents of food pathogens. Curr. Opin. Biotechnol. 2011, 22:157-163.
24. Matsuzaki S., Yasuda M., Nishikawa H., Kuroda M., Ujihara T., Shuin T., Shen Y., Jin Z., Fujimoto S., Nasimuzzaman M.D., Wakiguchi H., Sugihara S., Sugiura T., Koda S., Muraoka A., Imai S. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J. Infect. Dis. 2003, 187:613-624.
25. Miedzybrodzki R., Fortuna W., Weber-Dabrowska B., Górski A. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Post Med. Hig DoŚw. 2007, 61:461-465.
26. Miedzybrodzki R., Fortuna W., Weber-Dabrowska B., Górski A. A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin. Exp. Med. 2009, 9:303-312.
27. Pirnay J.P., De Vos D., Verbeken G., Merabishvili M., Chanishvili N., Vaneechoutte M., Zizi M., Laire G., Lavigne R., Huys I., Van den Mooter G., Buckling A., et al. The phage therapy paradigm: Prêt-à-porter or sur-mesure?. Pharm. Res. 2011, 28:934-937.
28. Pronk M.J., Pelger R.C., Baranski A.G., van Dam A., Arend S.M. Cure of chronic prostatitis presumably due to Enterococcus spp and gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 2006, 25:270-271.
29. Rhoads D.D., Wolcott R.D., Kuskowski M.A., Wolcott B.M., Ward L.S., Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J. Wound Care 2009, 18(237-238):240-243.
30. Rosenbaum P.R. Observational studies. Springer Series in Statistics 2002, 2nd Ed.
31. Schwartz S.D., Hubschman J.P., Heilwell G., Franco-Cardenas V., Pan C.K., Ostrick R.M., Mickunas E., Gay R., Klimanskaya I., Lanza R. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012, 379(9817):713-720.
32. Selgelid M.J. Ethics and drug resistance. Bioethics. 2007, 21:218-229.
33. Siddiqui A.R., Bernstein J.M. Chronic wound infection: Facts and controversies. Clin. Dermatol. 2010, 28:519-526.
34. Ślopek S., Durlakowa I., Weber-Dabrowska B., Kucharewicz-Krukowska A., Dabrowski M., Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. 1983, 31:267-291.
35. Ślopek S., Krzywy T. Morphology and ultrastructure of bacteriophages: An electron microscopic study. Arch. Immunol. Ther. Exp. 1985, 33:1-217.
36. Ślopek S., Weber-Dabrowska B., Dabrowski M., Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. 1987, 35:569-583.
37. Stafford N. Switzerland is to fund complementary therapies for six years while effectiveness is evaluated. BMJ 2011, 342:d819.
38. Sulakvelidze A., Kutter E. Phage therapy in humans. Bacteriophages: Biology and Applications 2005, 381-436. CRC Press, Boca Raton, FL. E. Kutter, A. Sulakvelidze (Eds.).
39. Trelińska J., Stolarska M., Zalewska-Szewczyk B., Kuzański W., Młynarski W. The use of bacteriophage therapy in Pseudomonas aeruginosa infection in patients with acute leukemias: Two cases report. Onkol. Pol. 2010, 13:50-53. [In Polish].
40. Turner M. Phage on the rampage: Antibiotics use may have driven the development of Europe's deadly. E. coli. Nature 2011, doi:10.1038/news.2011.360.
41. Turner M. German E. coli outbreak leads to drug trial. Nature 2011, doi: 10.1038/news.2011.332.
42. Vandenbroucke J.P. When are observational studies as credible as randomized trials?. Lancet 2004, 363:1728-1731.
43. Verbeken G., De Vos D., Vaneechoutte M., Merabishvili M., Zizi M., Pirnay J.P. European regulatory conundrum of phage therapy. Future Microbiol. 2007, 2:485-491.
44. Wang J., Hu B., Xu M., Yan Q., Liu S., Zhu X., Sun Z., Reed E., Ding L., Gong J., Li Q.Q., Hu J. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 2006, 17:309-317.
45. Weber-Dabrowska B., Mulczyk M., Górski A. Bacteriophage therapy of bacterial infections: An update of our institute's experience. Arch. Immunol. Ther. Exp. 2000, 48:547-551.
46. Weber-Dabrowska B., Mulczyk M., Górski A. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant. Proc. 2003, 35:1385-1386.
47. Wernli D., Haustein T., Conly J., Carmeli Y., Kichbusch I., Harbuth S. A call for action: The application of the international health regulations in the global health threat of antimicrobial resistance. PLoS Med. 2011, 8:e1001022.
48. Witoszka M., Strumillo B. Bacteriophage therapy of infected surgical wounds. Pol Tyg Lek. 1963, 18:430-432.
49. Wright A., Hawkins C.H., Anggård E.E., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009, 34:349-357.
50. Zimecki M., Weber-Dabrowska B., Łusiak-Szelachowska M., Mulczyk M., Boratyński J., Syper D., Górski A. Bacteriophages provide regulatory signals in mitogen-induced murine splenocyte proliferation. Cell. Mol. Biol. Lett. 2003, 8:700-711.